VVZ-2471

VVZ-2471 is an orally bioavailable small molecule dual modulator developed by Vivozon for the treatment of chronic and neuropathic pain, as well as substance use disorders. It functions as an inhibitor of the glycine transporter 2 (GlyT2) and an antagonist of the 5-hydroxytryptamine receptor 2A (5-HT2A). By inhibiting GlyT2, the drug increases glycine concentrations in the synaptic cleft of the spinal cord, enhancing inhibitory neurotransmission and suppressing pain signals. Its 5-HT2A antagonism provides additional analgesic effects and may mitigate the risk of drug-seeking behavior. Virginia Commonwealth University (VCU) has been a key collaborator in investigating the drug's safety and its potential application in treating substance use disorders, particularly for individuals using illicit substances.